Piper Sandler analyst Matthew O'Brien maintains $TransMedics (TMDX.US)$ with a buy rating, and maintains the target price at $180.
According to TipRanks data, the analyst has a success rate of 49.5% and a total average return of 4.6% over the past year.
Furthermore, according to the comprehensive report, the opinions of $TransMedics (TMDX.US)$'s main analysts recently are as follows:
TransMedics' third-quarter results fell short of expectations, and while the management has upheld its guidance for FY24, it suggests a broad spectrum of growth possibilities for the fourth quarter. Despite a sequential dip in transplant volumes across all three organ categories, the company maintains that it has not conceded any market share during the quarter. Analysts perceive the company as a dominant player in a market that remains largely untapped.
While there was an anticipation of a more subdued upside in Q3 for TransMedics, the actual performance shortfall was unexpected. Despite this, the company achieved significant growth of +64% and maintained its guidance for FY24. The challenges faced are seen as temporary and are not a result of market share loss or pricing pressure related to OCS disposables.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
派傑投資分析師Matthew O'Brien維持$TransMedics (TMDX.US)$買入評級，維持目標價180美元。
根據TipRanks數據顯示，該分析師近一年總勝率為49.5%，總平均回報率為4.6%。
此外，綜合報道，$TransMedics (TMDX.US)$近期主要分析師觀點如下：
TransMedics的第三季度業績低於預期，儘管管理層維持了對24財年的指導，但它表明第四季度存在廣泛的增長可能性。儘管所有三個器官類別的移植量連續下降，但該公司堅稱本季度沒有讓出任何市場份額。分析師認爲，該公司在仍未開發的市場中佔據主導地位。
儘管預計TransMedics在第三季度的上行空間將更加疲軟，但實際的業績不足卻出乎意料。儘管如此，該公司還是實現了+64％的顯著增長，並維持了24財年的預期。面臨的挑戰被視爲暫時性的，不是市場份額損失或與OCS一次性用品相關的定價壓力造成的。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
